Preview

Онкоурология

Расширенный поиск

Метастатический кастрационно-резистентный рак предстательной железы: современный взгляд на медикаментозную терапию и альтернативная регуляция опухолевых клеток

https://doi.org/10.17650/1726-9776-2018-14-1-107-116

Полный текст:

Аннотация

Рак предстательной железы (РПЖ) является одной из самых частых причин смерти от злокачественных новообразований у мужчин во многих странах мира. Передача сигнала в андрогенной оси регуляции имеет решающее значение для развития и прогрессирования РПЖ. Несмотря на постоянную зависимость от сигналов андрогенных рецепторов при кастрационной резистентности, использование новых антиандрогенных препаратов неизменно приводит к развитию резистентности к лечению. Взаимодействие андрогенрецепторного и альтернативного (фосфатидилинозитол-3-киназа, PI3K) путей в регуляции опухолевых клеток может быть одним из механизмов развития резистентности к терапии. В настоящей статье описываются современные методы лечения метастатического кастрационно-резистентного РПЖ и возможная роль пути PI3K в патогенезе и прогрессировании РПЖ.

Об авторах

Р. А. Гафанов
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия

Рустем Айратович Гафанов.

117997 Москва, ул. Профсоюзная, 86




С. В. Гармаш
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия

117997 Москва, ул. Профсоюзная, 86



И. Б. Кравцов
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия

117997 Москва, ул. Профсоюзная, 86



С. В. Фастовец
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России
Россия

117997 Москва, ул. Профсоюзная, 86



Список литературы

1. Ferlay J., Soerjomataram I., Ervik M. et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr.

2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30. DOI: 10.3322/caac.21332. PMID: 26742998.

3. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92. DOI: 10.1111/j.1742-1241.2011.02799.x. PMID: 21995694.

4. Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402–18. DOI: 10.1200/JCO.2015.64.2702. PMID: 26903579.

5. Logothetis C.J., Basch E., Molina A. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from COU-AA-301 randomised trial. Lancet Oncol 2012;13(12):1210–7. DOI: 10.1016/S14702045(12)70473-4. PMID: 23142059.

6. Basch E., Reeve B.B., Mitchell S.A. et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106(9):1–11. DOI: 10.1093/jnci/dju244. PMID: 25265940.

7. Fizazi K., Scher H.I., Miller K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomized, phase 3 AFFIRM trial. Lancet Oncol 2014;15(10):1147–56. DOI: 10.1016/S1470-2045(14)70303-1. PMID: 25104109.

8. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004;350(16): 1655–64. DOI: 10.1056/NEJMra030831. PMID: 15084698.

9. Pezaro C.J., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2013;65(2):270–3. DOI: 10.1016/j.eururo.2013.10.055. PMID: 24295792.

10. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. DOI: 10.1056/NEJMoa1209096. PMID: 23228172.

11. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI: 10.1056/NEJMoa1405095. PMID: 24881730.

12. Roviello G., Petrioli R., Laera L., Francini E. The third line of treatment for metastatic prostate cancer patients: options or strategy? Crit Rev Oncol Hematol 2015;95(3): 265–71. DOI: 10.1016/j.critrevonc.2015.04.010. PMID: 26052050.

13. Parker C., Gillessen S., Heidenreich A. et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v69–77. DOI: 10.1093/annonc/mdv222. PMID: 26205393.

14. Mohler J.L., Armstrong A.J., Bahnson R.R. et al. Prostate cancer, Version 1.2016. J Natl Compr Canc Netw 2016;14(1): 19–30. PMID: 26733552.

15. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513–20. DOI: 10.1056/NEJMoa041318. PMID: 15470214.

16. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720. PMID: 15470213.

17. Sweeney G.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46. DOI: 10.1056/NEJMoa1503747. PMID: 26244877.

18. James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024): 1163–77. DOI: 10.1016/S01406736(15)01037-5. PMID: 26719232.

19. Гафанов Р.А. Гормональная и химиотерапия у больных гормоночувствительным раком предстательной железы. Онкоурология 2016;12(1):63–8. DOI: 10.17650/1726-9776-2016-12-1-63-68.

20. Павлов А.Ю., Гафанов Р.А., Цыбульский А.Д. и др. Современная стратегия лекарственной терапии метастатического и кастрационно-резистентного рака предстательной железы. РМЖ 2016;(8):476–9.

21. Kantoff P.W., Higano C.S., Shore N.D. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411–22. DOI: 10.1056/NEJMoa1001294. PMID: 20818862.

22. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Oncol 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X. PMID: 20888992.

23. Oudard S., Fizazi K., Sengeløv L. et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial – FIRSTANA. J Clin Oncol 2017;35(28):3189–97. DOI: 10.1200/JCO.2016.72.1068. PMID: 28753384.

24. Li Z., Bishop A.C., Alyamani M. et al. Conversion of abiraterone to D4A drives antitumor activity in prostate cancer. Nature 2015;523(7560):347–51. DOI: 10.1038/nature14406. PMID: 26030522.

25. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI: 10.1056/NEJMoa1014618. PMID: 21612468.

26. Harland S., Staffurth J., Molina A. et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648–57. DOI: 10.1016/j.ejca.2013.07.144. PMID: 23973186.

27. Sternberg C.N., Molina A., North S. et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2013;24(4):1017– 25. DOI: 10.1093/annonc/mds585. PMID: 23152362.

28. Гафанов Р.А., Иванов С.А., Фастовец С.В. и др. Оценка эффективности и переносимости абиратерона ацетата (Зитига) у пациентов с метастатическим гормонорезистентным раком предстательной железы, у которых отмечалась прогрессия опухолевого процесса после химиотерапии таксанами. Современная онкология 2012;(2):25–8.

29. Ryan C.J., Smith M.R., Fizazi K. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2): 152–60. DOI: 10.1016/S14702045(14)71205-7. PMID: 25601341.

30. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI: 10.1056/NEJMoa1207506. PMID: 22894553.

31. Beer T.M., Armstrong A.J., Rathkopf D. et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 2017;71(2):151–4. DOI: 10.1016/j.eururo.2016.07.032. PMID: 27477525.

32. Алексеев Б.Я., Матвеев В.Б., Русаков И.Г. и др. Резолюция по итогам Совещания экспертов по лечению кастрационнорезистентного рака предстательной железы. Онкоурология 2016;12(3):109–10.

33. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI: 10.1056/NEJMoa1213755. PMID: 23863050.

34. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467–79. DOI: 10.1016/j.eururo.2013.11.002. PMID: 24321502.

35. Chi K.N., Annala M., Sunderland K. et al. A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer. J Clin Oncol 2017;35(15 Suppl).

36. van Soest R.J., van Royen M.E., de Morrée E.S. et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration resistant prostate cancer. Eur J Cancer 2013;49(18):3821–30. DOI: 10.1016/j.ejca.2013.09.026. PMID: 24200698.

37. Azad A.A., Volik S.V., Wyatt A.W. et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015;21(10):2315–24. DOI: 10.1158/1078-0432.CCR-14-2666. PMID: 25712683.

38. Romanel A., Gasi Tandefelt D., Conteduca V. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015;7(312):312re10. DOI: 10.1126/scitranslmed.aac9511. PMID: 26537258.

39. Caffo O., De Giorgi U., Fratino L. et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol 2015;68(1):147–53. DOI: 10.1016/j.eururo.2014.10.014. PMID: 25457020.

40. Harris V., Lloyd K., Forsey S. et al. A population-based study of prostate cancer chemotherapy. Clin Oncol 2011;23(10):706–8. DOI: 10.1016/j.clon.2011.04.014. PMID: 21602036.

41. Lissbrant I.F., Garmo H., Widmark A., Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol 2013;52(8):1593–601. DOI: 10.3109/0284186X.2013.770164. PMID: 23427879.

42. Onukwugha E., Mullins C.D., Hsu V.D. et al. Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer. Urology 2011;77(5):1088–95. DOI: 10.1016/j.urology.2010.11.059. PMID: 21439617.

43. Lafeuille M.H., Gravel J., Grittner A. et al. Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims disease. Am Health Drug Benefits 2013;6:307–16.

44. Chandrasekar T., Yang J.C., Gao A.C., Evans C.P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4(3):365–80. DOI: 10.3978/j.issn.2223-4683.2015.05.02. PMID: 26814148.

45. Watson P.A., Arora V.K., Sawyers C.L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15(12):701–11. DOI: 10.1038/nrc4016. PMID: 26563462.

46. Gao T., Furnari F., Newton A.C. PHLPP: a phosphatase that directly dephosphorylates AKT, promotes apoptosis, and suppresses tumor growth. Mol Cells 2005;18(1):13–24. DOI: 10.1016/j.molcel.2005.03.008. PMID: 15808505.

47. Eder I.E., Culig Z., Putz T. et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 2001;40(3):241–51. DOI: 49782. PMID: 11684838.

48. Leung J.K., Sadar M.D. Non-genomic actions of the androgen receptor in prostate cancer. Front Endocrinol (Lausanne) 2017;8:2. DOI: 10.3389/fendo.2017.00002. PMID: 28144231.

49. Davey R.A., Grossmann M. Androgen receptor structure, function and biology: From bench to bedside. Clin Biochem Rev 2016;37(1):3–15. PMID: 27057074.

50. Zarif J.C., Miranti C.K. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal 2016;28(5):348–56. DOI: 10.1016/j.cellsig.2016.01.013. PMID: 26829214.

51. Hobisch A., Eder I.E., Putz T. et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58(20):4640–5. PMID: 9788616.

52. Ueda T., Mawji N.R., Bruchovsky N., Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087–94. DOI: 10.1074/jbc.M203313200. PMID: 12163482.

53. Kim H.J., Lee W.J. Ligand-independent activation of the androgen receptor by insulin-like growth factor-I and the role of the MAPK pathway in skeletal muscle cells. Mol Cells 2009;28(6):589–93. DOI: 10.1007/s10059-009-0167-z. PMID: 19937471.

54. Kim H.J., Lee W.J. Insulin-like growth factor-I induces androgen receptor activation in differentiating C2C12 skeletal muscle cells. Mol Cells 2009;28(3):189–94. DOI: 10.1007/s10059-009-0118-8. PMID: 19705083.

55. Robinson D., Van Allen E.M., Wu Y.M. et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28. DOI: 10.1016/j.cell.2015.05.001. PMID: 26000489.

56. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497–510. DOI: 10.1038/onc.2008.245. PMID: 18794884.

57. Chen M.L., Xu P.Z., Peng X.D. et al. The deficiency of AKT1 is sufficient to suppress tumor development in Pten (+/–) mice. Genes Dev 2006;20(12):1569–74. DOI: 10.1101/gad.1395006. PMID: 16778075.

58. Gao H., Ouyang X., Banach-Petrosky W.A. et al. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1 Pten mice. Cancer Res 2006;66(16):7929–33. DOI: 10.1158/0008-5472.CAN-06-1637. PMID: 16912166.

59. Jiao J., Wang S., Qiao R. et al. Murine cell lines derived from PTEN null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007;67(13):6083– 91. DOI: 10.1158/0008-5472.CAN-064202. PMID: 17616663.

60. Carver B.S., Chapinski C., Wongvipat J. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19(5):575–86. DOI: 10.1016/j.ccr.2011.04.008. PMID: 21575859.

61. Mulholland D.J., Tran L.M., Li Y. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19(6):792–804. DOI: 10.1016/j.ccr.2011.05.006. PMID: 21620777.

62. Yoshimoto M., Cunha I.W., Coudry R.A. et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97(5):678–85. DOI: 10.1038/sj.bjc.6603924. PMID: 17700571.

63. Reid A.H., Attard G., Ambroisine L. et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010;102(4):678–84. DOI: 10.1038/sj.bjc.6605554. PMID: 20104229.

64. Antonarakis E.S., Keizman D., Zhang Z. et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012;118(24):6063–71. DOI: 10.1002/cncr.27689. PMID: 22674438.

65. Chaux A., Peskoe S.B., Gonzalez-Roibon N. et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012;25(11):1543–9. DOI: 10.1038/modpathol.2012.104. PMID: 22684219.

66. Zafarana G., Ishkanian A.S., Malloff C.A. et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012;118(16):4053–62. DOI: 10.1002/cncr.26729. PMID: 22281794.

67. Cuzick J., Yang Z.H., Fisher G. et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013;108(12):2582–9. DOI: 10.1038/bjc.2013.248. PMID: 23695019.

68. Barnett C.M., Heinrich M.C., Lim J. et al. Genetic profiling to determine risk of relapse free survival in high-risk localized prostate cancer. Clin Cancer Res 2014;20(5):1306–12. DOI: 10.1158/10780432.CCR-13-1775. PMID: 24352642.

69. Ferraldeschi R., Nava Rodrigues D., Riisnaes R. et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015;67(4):795–802. DOI: 10.1016/j.eururo.2014.10.027. PMID: 25454616.

70. Kim S.H., Kim S.H., Joung J.Y. et al. Overexpression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer. PLoS One 2015;10(4):e0122498. DOI: 10.1371/journal.pone.0122498. PMID: 25897494.

71. Hotte S.J., Eisenhauer E.A., Joshua A.M. et al. NCIC CTG, IND-205: a phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). ASCO Annual Meeting Abstracts 2013;31(15):5042.

72. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13(2):140–56. DOI: 10.1038/nrd4204. PMID: 24481312.

73. Hong D.S., Bowles D.W., Falchook G.S. et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18(15):4173–82. DOI: 10.1158/10780432.CCR-12-0714. PMID: 22693357.

74. Burris H.A. Safety, pharmacokinetics (pk), pharmacodynamics (pd), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 2011;29:3003.

75. Statz C.M., Patterson S.E., Mockus S.M. mTOR inhibitors in castration-resistant prostate cancer: a systematic review. Target Oncol 2017;12(1):47–59. DOI: 10.1007/s11523-016-0453-6. PMID: 27503005.

76. Rathkopf D.E., Larson S.M., Anand A. et al. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: phase 1/2 results and signaling pathway implications. Cancer 2015;121(21):3853–61. DOI: 10.1002/cncr.29578. PMID: 26178426.

77. Bendell J.C., Rodon J., Burris H.A. et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30(3):282–90. DOI: 10.1200/JCO.2011.36.1360. PMID: 22162589.

78. Hotte S.J., Joshua A.M., Torri V. et al. IND 205b: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. J Clin Oncol 2015;33:279.

79. Armstrong A.J., Halabi S., Healy P. et al. Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2015;33:5025.

80. de Bono J.S. Randomized phase II study of AKT blockade with ipatasertib (GDC0068) and abiraterone (abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy. J Clin Oncol 2016;34:5017.

81. Nakabayashi M., Werner L., Courtney K.D. et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012;110(11):1729–35. DOI: 10.1111/j.1464-410X.2012.11456.x. PMID: 22928480.

82. Qi W., Morales C., Cooke L.S. et al. Reciprocal feedback inhibition of the an drogen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget 2015;6(39):41976–87. DOI: 10.18632/oncotarget.5659. PMID: 26506516.

83. Thomas C., Lamoureux F., Crafter C. et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2013;12(11):2342–55. DOI: 10.1158/1535-7163.MCT-13-0032. PMID: 23966621.

84. Toren P., Kim S., Cordonnier T. et al. Combination AZD5363 with enzalutamide significantly delays enzalutamideresistant prostate cancer in preclinical models. Eur Urol 2015;67(6):986–90. DOI: 10.1016/j.eururo.2014.08.006. PMID: 25151012.

85. Arkenau H.T. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. J Clin Oncol 2014;32:2514.

86. Hancox U., Cosulich S., Hanson L. et al. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol Cancer Ther 2015;14(1):48–58. DOI: 10.1158/1535-7163.MCT-14-0406. PMID: 25398829.

87. Davies B.R., Greenwood H., Dudley P. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11(4):873–87. DOI: 10.1158/15357163.MCT-11-0824-T. PMID: 22294718.


Для цитирования:


Гафанов Р.А., Гармаш С.В., Кравцов И.Б., Фастовец С.В. Метастатический кастрационно-резистентный рак предстательной железы: современный взгляд на медикаментозную терапию и альтернативная регуляция опухолевых клеток. Онкоурология. 2018;14(1):107-116. https://doi.org/10.17650/1726-9776-2018-14-1-107-116

For citation:


Gafanov R.A., Garmash S.V., Kravtsov I.B., Fastovets S.V. Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulation. Cancer Urology. 2018;14(1):107-116. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-1-107-116

Просмотров: 277


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)